<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3483">
  <stage>Registered</stage>
  <submitdate>15/02/2012</submitdate>
  <approvaldate>15/02/2012</approvaldate>
  <nctid>NCT01550562</nctid>
  <trial_identification>
    <studytitle>Effects of Programming Parameters on Back Pain Relief in Subthreshold Spinal Cord Stimulation</studytitle>
    <scientifictitle>Precision High-Rate Sub-perception Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A7002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Low Back Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Boston Scientific Precision Plus spinal cord stimulation therapy

Placebo Comparator: Sham Stimulation - Sham subthreshold spinal cord stimulation therapy

Active Comparator: Treatment 1 - subthreshold spinal cord stimulation therapy

Experimental: Treatment 2 - subthreshold spinal cord stimulation therapy


Treatment: devices: Boston Scientific Precision Plus spinal cord stimulation therapy
Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain relief - Mean within-patient difference in average back pain intensity among treatment groups</outcome>
      <timepoint>4,8,and 12 days post temporary lead(s) implantation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pain relief responder rate - Difference in the proportion of subjects with =50% reduction in average back pain intensity among treatment groups</outcome>
      <timepoint>4,8,and 12 days post temporary lead(s) implantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Leg pain reduction - Mean within-patient difference in average leg pain intensity among treatment groups</outcome>
      <timepoint>4,8,and 12 days post temporary lead(s) implantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disability - Mean within-patient difference in disability among treatment groups</outcome>
      <timepoint>4,8,and 12 days post temporary lead(s) implantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent pain relief - Mean within-patient difference in overall percent pain relief among treatment groups</outcome>
      <timepoint>4,8,and 12 days post temporary lead(s) implantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life - Mean within-patient difference in quality of life among treatment groups</outcome>
      <timepoint>4,8,and 12 days post temporary lead(s) implantation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Chronic intractable pain of the trunk and/or limbs

          -  Documented history of trunk and/or limb pain of at least 180 days

          -  Average back pain intensity of 5 or greater on a 0-10 numerical rating scale during
             the 7-day period prior to the Screening Visit

          -  Pass study site's routine psychological/psychiatric evaluation within 180 days of the
             Trial Lead Insertion Visit

          -  If taking any medications for chronic pain, must be on a stable prescription during
             the 14-day period prior to the Trial Lead Insertion Visit and agree to continue on the
             same prescription throughout study participation

          -  Subject is willing and able to comply with all protocol-required procedures and
             assessments/evaluations

          -  Subject is able to independently read and complete all questionnaires and/or
             assessments provided in English

          -  18 years of age or older when written informed consent is obtained

          -  Subject signs a valid, Ethics Committee-approved informed consent form (ICF) provided
             in English</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Unable to operate the PrecisionPlus system

          -  Primary source of pain is cancer-related, pelvic, visceral, angina, or migraine

          -  Is a high surgical risk

          -  Is diabetic

          -  Is immunocompromised

          -  Currently on any anticoagulant medications that cannot be discontinued during
             perioperative period

          -  Untreated major depression or untreated generalized anxiety disorder

          -  Diagnosed with somatoform disorder, severe personality disorder, borderline
             personality disorder

          -  Diagnosed with any major psychiatric disorder not specifically listed in previous two
             exclusion criterion

          -  Currently diagnosed with cognitive impairment that would limit subject's ability to
             discern differences in pain severity, complete a pain diary, perform wound care

          -  Current abuse of alcohol or illicit drugs

          -  Subject requires Magnetic Resonance Imaging (MRI) while implanted with lead(s).

          -  Subject is participating (or intends to participate) in another investigational drug
             or device clinical trial that may influence the data that will be collected for this
             study

          -  Subject has previously undergone a spinal cord stimulation trial or is already
             implanted with an active implantable device(s) to treat their pain (IPGs, implantable
             drug pump, etc) or pacemaker or implantable cardiac defibrillator

          -  Patient is a woman who is not using adequate contraception, is pregnant or
             breastfeeding or intends to become pregnant during the course of the study (a urine
             pregnancy test must be performed within 28 days prior to the Trial Lead Insertion
             Visit in women of child-bearing potential and the test result document)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Hunter Pain Clinic - Newcastle</hospital>
    <postcode>2292 - Newcastle</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate the effects of varying programming parameters in
      subthreshold spinal cord stimulation therapy for pain relief.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01550562</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kay Adair</name>
      <address>Boston Scientific Corporation</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>